Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Rapid 90-Minute COVID-19 Test Shows High Accuracy in New Study

By LabMedica International staff writers
Posted on 21 Sep 2020
A 90-minute COVID-19 test has been shown to have over 94% sensitivity and 100% specificity in a new study.

In the study, scientists from the Imperial College London (London, UK) used high-speed tests which do not require a laboratory and can be performed in cartridges smaller than a mobile phone. More...
To perform the test, a pediatric-sized nose swab from a patient is inserted into the device, which then looks for traces of genetic material belonging to the SARS-CoV-2 virus, which causes COVID-19. A result is available within 90 minutes, compared to conventional COVID-19 testing which delivers a result in 24 hours.

The samples from all individuals in the study were analyzed on both the rapid-testing device, called the CovidNudge test, and standard hospital laboratory equipment - and then the results compared. The Lab-in-Cartridge rapid testing device, which can be performed at a patient’s bedside, was shown to have over 94% sensitivity and 100% specificity, suggesting a high level of accuracy and the ability to produce very few false negatives and no false positives. The test is now being developed for assessing simultaneously Flu-A, Flu-B, and RSV as well as COVID19.

“These results suggest the test, which can be performed at a patient’s bedside without the need to handle any sample material, has comparable accuracy to standard laboratory testing,” said Professor Graham Cooke, lead author of the study from the Department of Infectious Disease at Imperial. “Many tests involve a trade-off between speed and accuracy, but this test manages to achieve both. Developing an effective bedside test in under three months has been an incredible collaboration between teams of engineers, clinicians and virologists.”

Related Links:
Imperial College London


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Online QC Software
Acusera 24•7
Rapid Sepsis Test
SeptiCyte RAPID
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.